Edition:
United Kingdom

People: Resverlogix Corp (RVX.TO)

RVX.TO on Toronto Stock Exchange

2.57CAD
17 Sep 2019
Change (% chg)

-- (--)
Prev Close
$2.57
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
94,207
52-wk High
$4.94
52-wk Low
$2.57

Biln, Norma 

Mrs. Norma K. Biln Director of the company. She is the Chief Executive Officer and Co-Founder of Augurex. She has 22 years of experience in the pharmaceutical and biotech industries, commencing her career in clinical research with Pfizer Pharmaceuticals and held several positions in sales management, marketing and market access with Pfizer, Amgen and Abbott Laboratories where she won several regional and national level awards for top performance. Ms. Biln later joined Stressgen Biotechnologies as Director of Corporate Market Development and Director of Sales and Marketing for Stressgen Bioreagents. Before her role of CEO at Augurex, she worked in a senior consulting capacity with Aspreva Pharmaceuticals on Business Development, Commercial and Communications initiatives. Ms. Biln holds a Bachelor of Science and Master of Business Administration and is Chair of the Board of Directors of BioTalent Canada.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --